Separate names with a comma.
Evaluating passive physiological data collection during Spravato treatment...
Acquisitions of Biotechs - A Discussion concerning the possibility of a MindMed buyout over the next year... Acquisitions of drug companies,...
Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet...
Psychedelic Stocks: Focus on the Cash Podcast Listen to this... https://open.spotify.com/episode/3nZBsome6WoTEwMhaN8B5y
MindMed Reports Second Quarter 2024 Financial Results and Business Updates...
MindMed - Corporate Presentation - August 2024...
Patents Assigned to Mind Medicine, Inc. - Justia Patents Search https://patents.justia.com/assignee/mind-medicine-inc [SPOILER]
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference https://www.businesswire.com/news/home/20240806945771/en/ August 06,...
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update...
180,600 Shares in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Bought by Tidal Investments LLC...
Janus Henderson Group PLC Acquires New Stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)...
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer https://www.businesswire.com/news/home/20240729857388/en/ These type of...
Keep in mind they now have breakthrough designation. This will speed up their Phase 3. Check this video out from Dan Karlin:...
If you want layman's terms on why you should invest in this company. Look no further than here: Their latest Investor Presentation is here:...
This woke back up. Company is going into AI for sports betting handicapping. This is actually an interesting twist and valueable at that. Already...
Official press release from the patent issued yesterday https://finance.yahoo.com/news/mindmed-announces-issuance-patent-mm120-110000178.html
I wish I have
MNMD - MindMed - Patent July 19 - LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC U.S....
MindMed to be Included in Russell 2000® and Russell 3000® Indexes...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial...
